Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $294.3 million.

  • PROCEPT BioRobotics' Cash & Equivalents rose 4956.19% to $294.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $294.3 million, marking a year-over-year increase of 4956.19%. This contributed to the annual value of $333.7 million for FY2024, which is 2974.2% up from last year.
  • PROCEPT BioRobotics' Cash & Equivalents amounted to $294.3 million in Q3 2025, which was up 4956.19% from $302.7 million recorded in Q2 2025.
  • PROCEPT BioRobotics' Cash & Equivalents' 5-year high stood at $333.7 million during Q4 2024, with a 5-year trough of $86.1 million in Q1 2021.
  • In the last 5 years, PROCEPT BioRobotics' Cash & Equivalents had a median value of $257.2 million in 2023 and averaged $244.9 million.
  • In the last 5 years, PROCEPT BioRobotics' Cash & Equivalents surged by 23011.45% in 2022 and then crashed by 4451.9% in 2023.
  • Over the past 5 years, PROCEPT BioRobotics' Cash & Equivalents (Quarter) stood at $304.3 million in 2021, then dropped by 27.1% to $221.9 million in 2022, then rose by 15.94% to $257.2 million in 2023, then rose by 29.74% to $333.7 million in 2024, then decreased by 11.82% to $294.3 million in 2025.
  • Its Cash & Equivalents stands at $294.3 million for Q3 2025, versus $302.7 million for Q2 2025 and $316.2 million for Q1 2025.